Search results for "From ACP Journal Club"
Risk scores overestimated risk for CVD in newly diagnosed type 2 diabetes
Available risk scores are in need of recalibration but still serve as useful decision-making tools, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2018/12/14/8.htm
14 Dec 2018
SGLT2 inhibitors reduce all-cause mortality
A recent meta-analysis found lowered mortality risk with sodium-glucose cotransporter-2 (SGLT2) inhibitors, and an ACP Journal Club commentary added that other trials have shown beneficial effects of the drug class on kidney function in patients with type 2 diabetes.
https://diabetes.acponline.org/archives/2021/05/14/6.htm
14 May 2021
Studies analyze amputation rates with sodium–glucose cotransporter-2 inhibitors
An ACP Journal Club commentary looked at studies on the effects of canagliflozin in patients with cardiovascular disease and dapagliflozin in patients with peripheral artery disease, concluding that amputation risks are small enough that they needn't play a major role in prescribing decisions.
https://diabetes.acponline.org/archives/2021/02/12/7.htm
12 Feb 2021
In stable CAD with type 2 diabetes, adding ticagrelor to aspirin reduced CV events but increased major bleeding
Although an industry-funded trial found little net benefit overall from adding ticagrelor to aspirin, it's possible that some patients with higher ischemic risk and low bleeding risk could benefit, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2020/02/14/6.htm
14 Feb 2020
In screen-detected type 2 diabetes, intensive therapy did not differ from usual care for CV events at 10 years
Despite the lack of observed benefit in this analysis, primary care physicians should continue to operate under the reasonable assumption that addressing cardiovascular (CV) risk factors improves longevity, said an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2020/05/08/6.htm
8 May 2020
In acute ischemic stroke with hyperglycemia, intensive vs standard glucose control did not improve 90-day outcomes
Several factors, including high rates of reperfusion therapy and early hospital discharge, may explain why this trial found no benefit from intensive glucose control after stroke, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2020/01/10/7.htm
10 Jan 2020
In type 2 diabetes, early metformin plus vildagliptin reduced treatment failure vs a stepwise approach
Despite this study's findings, clinicians should continue to follow guidelines and use metformin as the first-line drug intervention, then select from other drug classes when there is a compelling indication, advised an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2020/03/13/7.htm
13 Mar 2020
Dapagliflozin reduced cardiorenal outcomes but not MACE in T2 diabetes with or at risk for atherosclerotic CVD
Baseline kidney disease, albuminuria, and cardiovascular disease (CVD) status may help determine which patients will benefit most from sodium-glucose cotransporter-2 inhibitors, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2019/11/08/7.htm
8 Nov 2019
Continuous glucose monitoring reduced hypoglycemia over 6 months
The positive results of a trial of continuous glucose monitoring in type 1 diabetes patients ages 60 years and older support recommending the technology to this group, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2020/12/11/10.htm
11 Dec 2020
In type 2 diabetes, intensive glucose control for 5.6 years did not differ from usual care for major CV events at 14 years
These long-term follow-up data show no legacy effect from intensive glucose control on cardiovascular (CV) events, differing from the results of the United Kingdom Prospective Diabetes Study, an ACP Journal Club commentary noted.
https://diabetes.acponline.org/archives/2019/10/11/8.htm
11 Oct 2019